Immunoadjuvant from Cha Vaccine Institute Used in COVID-19 Vaccine Development by Chinese Company

[Asia Economy Reporter Cho Hyun-ui] Chabiontech affiliate Chavaccine Research Institute announced on the 1st that its self-developed immune adjuvant will be used in the development of a novel coronavirus infection (COVID-19) vaccine.

Chavaccine Research Institute signed a Material Transfer Agreement (MTA) with Chinese vaccine developer CanSino Biologics and decided to provide its immune adjuvant as a candidate technology for COVID-19 vaccine development.

The immune adjuvant technology of Chavaccine Research Institute enables simultaneous induction of humoral immunity, which activates antibody production, and cellular immunity, which eliminates virus-infected cells. It is explained that its effectiveness is significantly higher compared to other immune adjuvants that mainly have humoral immune functions.

CanSino Biologics is a company that researches and develops vaccines such as Ebola vaccine, meningitis vaccine, and shingles vaccine. Established in Tianjin, China in 2009, it was listed on the Hong Kong Stock Exchange in March last year. It possesses technology to generate recombinant protein antigens that carry viral characteristics by removing part of the virus's genes, making them harmless to the human body.

This content was produced with the assistance of AI translation services.